Nonsurgical Approach in Stage I and Stage II Breast Cancer

References

• American Joint Committee on Cancer. Manual for Strategy of Cancer, 3rded. JB Lippincott, Philadelphia 1988; 145–150
   Google Scholar
• De Maublanc M A. Cytoponctions et cancers du sein: diagnostic, prognostic, dosage des recepteurs hormonaux. Neoadjuvant Chemotherapy, CI Jacquillat, M Weil, D Khayat. John Libbey Eurotext, Paris 1986; 181–188
   Google Scholar
• Rochefort H, Capony F, Garcia M. Estrogen induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis. J Cell Biochem 1987; 35: 17–29
   PubMed Web of Science ®Google Scholar
• Jacquillat C I, Weil M, Baillet F. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119–129
   PubMed Web of Science ®Google Scholar
• Jacquillat C I, Weil M, Auclerc G (1991) Ten years of breast preserving management in infiltrative breast cancer: results in 412 patients treated by neoadjuvant chemotherapy and radiation therapy with or without hormonotherapy. Proceeding of the 3rd International Congress on Neoadjuvant Chemotherapy. 1991, CI Jacquillat, M Weil, D Khayat. Springer-Verlag, Paris, 126–135
   Google Scholar
• Weil M, Khayat D, Ch Borel. Promising preliminary results with a combination including cis.platinum (CDDP)/VP. 16/5 FU and alternatively pretreated metastatic breast cancer (BC) and in primary resistant BC (protocol (P) 01VP87). Proc Am Soc Clin Oncol 1989; 8: 49, (abstr)
   Google Scholar
• Roger P P, Groshen S, Saigo P E. Pathological prognostic factors in stage I (Tl NO MO) and stage II (Tl Nl) breast carcinoma a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239–1251
   PubMed Web of Science ®Google Scholar
• Fisher B, Gebhardt M. The evolution of breast cancer surgery: past, present and future. Semin Oncol 1987; 5: 385–394
   Google Scholar
• Fisher B, Carbone P, Economou S G. Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975; 292: 117–122
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–410
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681–1692
   PubMed Web of Science ®Google Scholar
• Jacquillat C I, Baillet F, Auclerc G. Initial chemotherapy + conservation radiotherapy in stages I, II and III breast cancer. Proceeding of the 13th International Cancer Congress, Seattle, WA, September, 1982, (abstr)
   Google Scholar
• Jacquillat C I, Baillet F, Weil M. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer 1988; 61: 1977–1982
   PubMed Web of Science ®Google Scholar
• De Vita V T. On the value of response criteria in therapeutic research. Neoadjuvant Chemotherapy, CI Jacquillat, M Weil, D Khayat. John Libbey Eurotext, Paris 1988; 3
   Google Scholar
• Calle R, Pilleron J P, Schlienger P, Vilcoq J R. Conservative management of operable breast cancer. Cancer 1978; 42: 2045–2053
   PubMed Web of Science ®Google Scholar
• Osborne M, Ormiston N, Harmer C. Breast conservation in the treatment of early breast cancer. Cancer 1984; 53: 349–355
   PubMed Web of Science ®Google Scholar
• Veronesi U, Saccozzi R, Del Vecchio M. Comparing radical mastectomy with quandrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305: 6–11
   PubMed Web of Science ®Google Scholar
• Delouche G. Le traitement conservateur des petits cancers du sein opérables. 30 années d'expgrience. Le traitement conservateur du cancer du sein, F Baillet. Langres, Cedem 1988; 51
   Google Scholar
• Montbardon X, Gerard J P, De Laroche G. Cancer du sein: traitement conservateur du cancer du sein a Lyon: a propos de lOOOcasde 1950a 1986. Le traitement conservateur du cancer du sein, F Baillet. Langres, Cedem 1988; 61
   Google Scholar
• Vilcoq J R, Fourquet A, Campana F. Cancer du sein: traitement conservateur a l'lnstitut Curie. Le traitement conservateur du sein, F Baillet. Langres, Cedem 1988; 149–159
   Google Scholar
• Pierquin B, Raynal M, Otmezguine Y. Le traitement conservateur des cancers du sein: rtsultats a 13 ans. Le traitement conservateur du cancer du sein, F Baillet. Langres, Cedem 1988; 67
   Google Scholar
• Margolese R G, Begin L. Surgical techniques for breast conserving surgery after preoperative chemotherapy. The NSABP experience. Proceeding of the Third International Congress, CI Jacquillat, M Weil, D Khayat. Springer-Verlag, Paris 1991; 151–153
   Google Scholar
• Belembaogo E, Vernis M, Chollet P. Neoadjuvant chemotherapy in 101 noninflammatory breast cancers: treatment results. Proceeding of the Third International Congress, CI Jacquillat, M Weil, D Khayat. Springer-Verlag, Paris 1991; 154–157
   Google Scholar
• Mauriac M, Durand M M, Avril A, Dilhuydy J M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 1991; 2: 347–354
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Veronesi U, Brambilla C. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539–1545
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Dimitro N V. A randomized clinical trial evaluating sequential methotrexate and fluorouracile in the treatment of patients with node negative breast cancer who have estrogen receptor negative tumors. N Engl J Med 1989; 320: 473–478
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res 1988; 48: 2314–2324
   PubMed Web of Science ®Google Scholar
• Mansour E G, Gray R, Shatila A H. Efficacy of adjuvant chemotherapy in high-risk node negative breast cancer. N Engl J Med 1989; 320: 485–490
   PubMed Web of Science ®Google Scholar
• Clinical alert from the National Cancer Institute. Breast Cancer Res Treat 1988; 12: 3–5
   PubMed Web of Science ®Google Scholar
• Sigurdsson H, Baldetorp B, Borg A. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045–1053
   PubMed Web of Science ®Google Scholar